SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45
Angiotensin-Converting Enzyme 2
/ genetics
Animals
COVID-19
/ genetics
Endothelial Cells
/ metabolism
Hematopoietic Stem Cells
/ metabolism
Humans
Inflammasomes
/ genetics
Leukocyte Common Antigens
/ genetics
NLR Family, Pyrin Domain-Containing 3 Protein
/ genetics
SARS-CoV-2
/ genetics
Serine Endopeptidases
/ genetics
Spike Glycoprotein, Coronavirus
/ genetics
Virus Internalization
ACE2
COVID19
Cytokine storm
Hematopoietic stem cells
Nlrp3 inflammasome
Pyroptosis
SARS-CoV-2
Spike protein
VSELs
Journal
Stem cell reviews and reports
ISSN: 2629-3277
Titre abrégé: Stem Cell Rev Rep
Pays: United States
ID NLM: 101752767
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
pubmed:
22
7
2020
medline:
3
3
2021
entrez:
22
7
2020
Statut:
ppublish
Résumé
Angiotensin-converting enzyme 2 (ACE2) plays an important role as a member of the renin-angiotensin-aldosterone system (RAAS) in regulating the conversion of angiotensin II (Ang II) into angiotensin (1-7) (Ang [1-7]). But at the same time, while expressed on the surface of human cells, ACE2 is the entry receptor for SARS-CoV-2. Expression of this receptor has been described in several types of cells, including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which raises a concern that the virus may infect and damage the stem cell compartment. We demonstrate for the first time that ACE2 and the entry-facilitating transmembrane protease TMPRSS2 are expressed on very small CD133
Identifiants
pubmed: 32691370
doi: 10.1007/s12015-020-10010-z
pii: 10.1007/s12015-020-10010-z
pmc: PMC7370872
doi:
Substances chimiques
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
NLRP3 protein, human
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Leukocyte Common Antigens
EC 3.1.3.48
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Serine Endopeptidases
EC 3.4.21.-
TMPRSS2 protein, human
EC 3.4.21.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
266-277Subventions
Organisme : NIH HHS
ID : 2R01 DK074720
Pays : United States
Références
Fleming, I. (2006). Signaling by the angiotensin-converting enzyme. Circ Res, 98(7), 887–896.
pubmed: 16614314
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J. C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020). Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ Res, 126(10), 1456–1474.
pubmed: 32264791
Schwacke, J. H., Spainhour, J. C., Ierardi, J. L., Chaves, J. M., Arthur, J. M., Janech, M. G., et al. (2013). Network modeling reveals steps in angiotensin peptide processing. Hypertension, 61(3), 690–700.
pubmed: 23283355
pmcid: 5001166
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., et al. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426(6965), 450–454.
pubmed: 14647384
pmcid: 7095016
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., Bao, L., Zhang, B., Liu, G., Wang, Z., Chappell, M., Liu, Y., Zheng, D., Leibbrandt, A., Wada, T., Slutsky, A. S., Liu, D., Qin, C., Jiang, C., & Penninger, J. M. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 11(8), 875–879.
pubmed: 7095783
pmcid: 7095783
Joshi, S., Wollenzien, H., Leclerc, E., & Jarajapu, Y. P. (2019). Hypoxic regulation of angiotensin-converting enzyme 2 and mas receptor in human CD34(+) cells. J Cell Physiol, 234(11), 20420–20431.
pubmed: 30989646
pmcid: 6660366
Rodgers, K. E., Xiong, S., Steer, R., & diZerega, G. S. (2000). Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells, 18(4), 287–294.
pubmed: 10924095
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280 e278.
pubmed: 7102627
pmcid: 7102627
Chappell, M. C., Pirro, N. T., Sykes, A., & Ferrario, C. M. (1998). Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension, 31(1 Pt 2), 362–367.
pubmed: 9453329
Singh, K. D., & Karnik, S. S. (2016). Angiotensin receptors: Structure, function, signaling and clinical applications. J Cell Signal, 1(2).
Ren, X. S., Tong, Y., Ling, L., Chen, D., Sun, H. J., Zhou, H., Qi, X. H., Chen, Q., Li, Y. H., Kang, Y. M., & Zhu, G. Q. (2017). NLRP3 gene deletion attenuates angiotensin II-induced phenotypic transformation of vascular smooth muscle cells and vascular remodeling. Cellular Physiology and Biochemistry, 44(6), 2269–2280.
pubmed: 29262411
Zhao, M., Bai, M., Ding, G., Zhang, Y., Huang, S., Jia, Z., & Zhang, A. (2018). Angiotensin II stimulates the NLRP3 Inflammasome to induce Podocyte injury and mitochondrial dysfunction. Kidney Dis (Basel), 4(2), 83–94.
Chen, I. Y., Moriyama, M., Chang, M. F., & Ichinohe, T. (2019). Severe acute respiratory syndrome coronavirus Viroporin 3a activates the NLRP3 Inflammasome. Frontiers in Microbiology, 10, 50.
pubmed: 30761102
pmcid: 6361828
Gan, W., Ren, J., Li, T., Lv, S., Li, C., Liu, Z., & Yang, M. (2018). The SGK1 inhibitor EMD638683, prevents angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochim Biophys Acta Mol Basis Dis, 1864(1), 1–10.
pubmed: 28986310
Jarajapu, Y. P. (2020). Targeting ACE2/angiotensin-(1-7)/mas receptor Axis in the vascular progenitor cells for cardiovascular diseases. Molecular Pharmacology, mol.119.117580.
Swanson, K. V., Deng, M., & Ting, J. P. (2019). The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat Rev Immunol, 19(8), 477–489.
pubmed: 31036962
pmcid: 7807242
Ratajczak, M. Z., Bujko, K., Cymer, M., Thapa, A., Adamiak, M., Ratajczak, J., Abdel-Latif, A. K., & Kucia, M. (2020). The Nlrp3 inflammasome as a "rising star" in studies of normal and malignant hematopoiesis. Leukemia, 34(6), 1512–1523.
pubmed: 32313108
pmcid: 7266743
Franchi, L., Munoz-Planillo, R., & Nunez, G. (2012). Sensing and reacting to microbes through the inflammasomes. Nat Immunol, 13(4), 325–332.
pubmed: 22430785
pmcid: 3449002
Ratajczak, M. Z., Adamiak, M., Thapa, A., Bujko, K., Brzezniakiewicz-Janus, K., & Lenkiewicz, A. M. (2019). NLRP3 inflammasome couples purinergic signaling with activation of the complement cascade for the optimal release of cells from bone marrow. Leukemia, 33(4), 815–825.
pubmed: 30846866
pmcid: 6477784
Lenkiewicz, A. M., Adamiak, M., Thapa, A., Bujko, K., Pedziwiatr, D., Abdel-Latif, A. K., Kucia, M., Ratajczak, J., & Ratajczak, M. Z. (2019). The Nlrp3 Inflammasome orchestrates mobilization of bone marrow-residing stem cells into peripheral blood. Stem Cell Rev Rep, 15(3), 391–403.
pubmed: 31089880
Mori, J., Oudit, G. Y., & Lopaschuk, G. D. (2020). SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism. American Journal of Physiology. Endocrinology and Metabolism, 319, E43–E47.
pubmed: 32469255
pmcid: 7322507
Sagulenko, V., Thygesen, S. J., Sester, D. P., Idris, A., Cridland, J. A., Vajjhala, P. R., Roberts, T. L., Schroder, K., Vince, J. E., Hill, J. M., Silke, J., & Stacey, K. J. (2013). AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ, 20(9), 1149–1160.
pubmed: 23645208
pmcid: 3741496
Ratajczak, M. Z., & Kucia, M. (2020). SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells. Leukemia, 34, 1726–1729.
Ratajczak, J., Zuba-Surma, E., Klich, I., Liu, R., Wysoczynski, M., Greco, N., Kucia, M., Laughlin, M. J., & Ratajczak, M. Z. (2011). Hematopoietic differentiation of umbilical cord blood-derived very small embryonic/epiblast-like stem cells. Leukemia Aug, 25(8), 1278–1285.
Kassmer, S. H., Jin, H., Zhang, P. X., Bruscia, E. M., Heydari, K., Lee, J. H., Kim, C. F., Kassmer, S. H., & Krause, D. S. (2013). Very small embryonic-like stem cells from the murine bone marrow differentiate into epithelial cells of the lung. Stem Cells, 31(12), 2759–2766.
pubmed: 23681901
pmcid: 4536826
Guerin, C. L., Loyer, X., Vilar, J., Cras, A., Mirault, T., Gaussem, P., Silvestre, J. S., & Smadja, D. M. (2015). Bone-marrow-derived very small embryonic-like stem cells in patients with critical leg ischaemia: Evidence of vasculogenic potential. Thromb Haemost, 113(5), 1084–1094.
pubmed: 25608764
Chen, Z. H., Lv, X., Dai, H., Liu, C., Lou, D., Chen, R., & Zou, G. M. (2015). Hepatic regenerative potential of mouse bone marrow very small embryonic-like stem cells. J Cell Physiol, 230(8), 1852–1861.
pubmed: 25545634
Havens, A. M., Shiozawa, Y., Jung, Y., Sun, H., Wang, J., McGee, S., Mishra, A., Taichman, L. S., Danciu, T., Jiang, Y., Yavanian, G., Leary, E., Krebsbach, P. H., Rodgerson, D., & Taichman, R. S. (2013). Human very small embryonic-like cells generate skeletal structures, in vivo. Stem Cells Dev, 22(4), 622–630.
pubmed: 23020187
Wojakowski, W., Tendera, M., Kucia, M., Zuba-Surma, E., Paczkowska, E., Ciosek, J., Hałasa, M., Król, M., Kazmierski, M., Buszman, P., Ochała, A., Ratajczak, J., Machaliński, B., & Ratajczak, M. Z. (2009). Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction. J Am Coll Cardiol, 53(1), 1–9.
pubmed: 19118716
pmcid: 5536894
Kuruca, S. E., Celik, D. D., Ozerkan, D., & Erdemir, G. (2019). Characterization and isolation of very small embryonic-like (VSEL) stem cells obtained from various human hematopoietic cell sources. Stem Cell Rev Rep, 15(5), 730–742.
pubmed: 31172457
Chang, Y. J., Tien, K. E., Wen, C. H., Hsieh, T. B., & Hwang, S. M. (2014). Recovery of CD45(−)/Lin(−)/SSEA-4(+) very small embryonic-like stem cells by cord blood bank standard operating procedures. Cytotherapy, 16(4), 560–565.
pubmed: 24364909
Monti, M., Imberti, B., Bianchi, N., Pezzotta, A., Morigi, M., Del Fante, C., et al. (2017). A novel method for isolation of pluripotent stem cells from human umbilical cord blood. Stem Cells Dev, 26(17), 1258–1269.
pubmed: 28583028
Ganguly, R., Metkari, S., & Bhartiya, D. (2018). Dynamics of bone marrow VSELs and HSCs in response to treatment with gonadotropin and steroid hormones, during pregnancy and evidence to support their asymmetric/symmetric cell divisions. Stem Cell Rev Rep, 14(1), 110–124.
pubmed: 29168113
Shaikh, A., Nagvenkar, P., Pethe, P., Hinduja, I., & Bhartiya, D. (2015). Molecular and phenotypic characterization of CD133 and SSEA4 enriched very small embryonic-like stem cells in human cord blood. Leukemia, 29(9), 1909–1917.
pubmed: 25882698
Virant-Klun, I. (2018). Functional testing of primitive oocyte-like cells developed in ovarian surface epithelium cell culture from small VSEL-like stem cells: Can they be fertilized one day? Stem Cell Rev Rep, 14(5), 715–721.
pubmed: 29876729
Park, C., Ma, Y. D., & Choi, K. (2005). Evidence for the hemangioblast. Exp Hematol, 33(9), 965–970.
pubmed: 16140143
Lis, R., Karrasch, C. C., Poulos, M. G., Kunar, B., Redmond, D., Duran, J. G. B., et al. (2017). Conversion of adult endothelium to immunocompetent haematopoietic stem cells. Nature, 545(7655), 439–445.
pubmed: 28514438
pmcid: 5794215
Ribatti, D. (2008). Hemangioblast does exist. Leuk Res, 32(6), 850–854.
pubmed: 18192009
Lacaud, G., & Kouskoff, V. (2017). Hemangioblast, hemogenic endothelium, and primitive versus definitive hematopoiesis. Exp Hematol, 49, 19–24.
pubmed: 28043822
Guthrie, S. M., Curtis, L. M., Mames, R. N., Simon, G. G., Grant, M. B., & Scott, E. W. (2005). The nitric oxide pathway modulates hemangioblast activity of adult hematopoietic stem cells. Blood, 105(5), 1916–1922.
pubmed: 15546953
Zambidis, E. T., Park, T. S., Yu, W., Tam, A., Levine, M., Yuan, X., et al. (2008). Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood, 112(9), 3601–3614.
pubmed: 18728246
pmcid: 2572789
Latz, E., Xiao, T. S., & Stutz, A. (2013). Activation and regulation of the inflammasomes. Nat Rev Immunol, 13(6), 397–411.
pubmed: 23702978
Groslambert, M., & Py, B. F. (2018). Spotlight on the NLRP3 inflammasome pathway. Journal of Inflammation Research, 11, 359–374.
pubmed: 30288079
pmcid: 6161739
Jo, E. K., Kim, J. K., Shin, D. M., & Sasakawa, C. (2016). Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol, 13(2), 148–159.
pubmed: 26549800
Suresh, R., Chandrasekaran, P., Sutterwala, F. S., & Mosser, D. M. (2016). Complement-mediated 'bystander' damage initiates host NLRP3 inflammasome activation. J Cell Sci, 129(9), 1928–1939.
pubmed: 27006116
pmcid: 4893798
Roh, J. S., & Sohn, D. H. (2018). Damage-associated molecular patterns in inflammatory diseases. Immune Netw, 18(4), e27.
pubmed: 30181915
pmcid: 6117512
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020). DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol, 20(2), 95–112.
pubmed: 31558839
Meng, Y., Pan, M., Zheng, B., Chen, Y., Li, W., Yang, Q., Zheng, Z., Sun, N., Zhang, Y., & Li, X. (2019). Autophagy attenuates angiotensin II-induced pulmonary fibrosis by inhibiting redox imbalance-mediated NOD-like receptor family Pyrin domain containing 3 Inflammasome activation. Antioxid Redox Signal, 30(4), 520–541.
pubmed: 29486589
Lim, S., Lee, M. E., Jeong, J., Lee, J., Cho, S., Seo, M., & Park, S. (2018). sRAGE attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting RAGE-NFkappaB-NLRP3 activation. Inflamm Res, 67(8), 691–701.
pubmed: 29796842
Kohlstedt, K., Gershome, C., Friedrich, M., Muller-Esterl, W., Alhenc-Gelas, F., Busse, R., & Fleming, I. (2006). Angiotensin-converting enzyme (ACE) dimerization is the initial step in the ACE inhibitor-induced ACE signaling cascade in endothelial cells. Mol Pharmacol, 69(5), 1725–1732.
pubmed: 16476786
Slukvin, I. I. (2009). Renin-angiotensin system and hemangioblast development from human embryonic stem cells. Expert Rev Hematol, 2(2), 137–143.
pubmed: 21083448
Jokubaitis, V. J., Sinka, L., Driessen, R., Whitty, G., Haylock, D. N., Bertoncello, I., et al. (2008). Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood, 111(8), 4055–4063.
pubmed: 17993616
Mizuochi, C., Fraser, S. T., Biasch, K., Horio, Y., Kikushige, Y., Tani, K., Akashi, K., Tavian, M., & Sugiyama, D. (2012). Intra-aortic clusters undergo endothelial to hematopoietic phenotypic transition during early embryogenesis. PLoS One, 7(4), e35763.
pubmed: 22558218
pmcid: 3338791
Ratajczak, M. Z., Ratajczak, J., & Kucia, M. (2019). Very small embryonic-like stem cells (VSELs) an update and future directions. Circulation Research, 124(2), 208–210.